Accelerating Novel Peptides into Clinical Trials with Integrated Partnership

Do you have peptide drug candidates in development? Attend our webinar co-presented by Yen-Huei Lin, Ph.D. Exec. Director, Biopharmaceutical Development and Manufacturing at Neuraly and William Fang, Head of Oligo/Peptide Business at WuXi STA about how an integrated CMC partnership was critical in accelerating a novel peptide to phase 1 clinical trial.